产品
编 号：F746016
分子式：C31H29FNNaO5
分子量：537.55
分子式：C31H29FNNaO5
分子量：537.55
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1604815-32-8
产品详情
生物活性：
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
Mavodelpar (10 mg/kg；腹腔注射，10 mg/kg，每日 1 次，6-17 周龄) 可有效抑制肾小球损伤和肾纤维化，并降低纤维化相关蛋白的水平。Animal Model:Male and female B6129SF1-Col4a3-/- mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age
Result:Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
Mavodelpar (10 mg/kg；腹腔注射，10 mg/kg，每日 1 次，6-17 周龄) 可有效抑制肾小球损伤和肾纤维化，并降低纤维化相关蛋白的水平。Animal Model:Male and female B6129SF1-Col4a3-/- mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age
Result:Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备